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 CORRESPONDENCE ORRESPONDENCE 
 Re: Detection of Hypermethyl-
ated Genes in Women With and 
Without Cervical Neoplasia 
 Feng et al.  ( 1 ) examined whether 
changes in DNA methylation of 20 genes, 
selected on the basis of their role in cer-
vical cancer, could be used as markers of 
cervical intraepithelial neoplasia (CIN) 
and invasive cervical cancer (ICC). The 
authors found varying frequencies of 
promoter hypermethylation in these 20 
genes in 319 exfoliated cell samples and 
matched tissue biopsy specimens. For 
four of these genes (DAPK1, RARB, 
TWIST1, and CDH13), increasing fre-
quency of hypermethylation was statis-
tically signifi cantly associated with 
increasing severity of disease. The esti-
mated specifi city of the three-gene panel 
(DAPK, RARB, and TWIST1) was 95%, 
which is higher than specifi cities  re ported 
for cytology and human papillomavirus 
(HPV) testing  ( 1 ) . Although the study 
was well designed and a molecular ge-
netic test with high specifi city such as 
this one is needed, some of the fi ndings 
are inconsistent with previously reported 
results and the conclusions may there-
fore not be valid. 
 We believe that the following points 
are important to consider when interpret-
ing the results of Feng et al. First, the 
high frequency of hypermethylation in 
the SFN, HIC1, and APC genes observed 
in the samples of histologically normal 
cells and atypical squamous cells of 
 undetermined signifi cance (ASCUS) is 
unusual. Although low frequency of meth-
 ylation in a group consisting of ASCUS 
compared with CIN and ICC is not 
 unexpected because of the diagnostic di-
lemma involved in classifying these cy-
tologic changes into specifi c diagnostic 
categories, none of the previous studies 
reported such a high frequency of pro-
moter hypermethylation for HIC1 and 
APC in normal cervical epithelium or 
other normal tissues  ( 2 – 5 ) . In fact, in our 
series of normal and ASCUS ( N = 59) 
and ICC ( N = 82) specimens, we ob-
served a different pattern of promoter 
hypermethylation in these two genes. 
That is, we saw promoter hypermethyl-
ation in 4% and 0% of the normal/ 
ASCUS group and 18.3% and 11% in 
ICC for HIC1 and APC genes, respec-
tively. Similarly, the authors reported a 
higher frequency of promoter hyper-
methylation of SFN than has been seen 
in previous studies  ( 6 , 7 ) . Misclassifi ca-
tion of methylation could occur due to 
amplifi cation of nonspecifi c targets in 
the genome, which ultimately makes the 
results on these three genes diffi cult to 
interpret. Whether these genes have util-
ity in cervical cancer screening needs to 
be confi rmed in other studies. 
 A number of previous studies have 
also shown a high frequency of promoter 
hypermethylation of DAPK, CDH1, 
RARB, and p16 in ICC  ( 2 – 4 ) . However, 
the frequency of promoter hypermethyl-
ation of these genes in CIN lesions was 
not well studied. Thus, well-designed 
studies of CIN are required to determine 
whether inclusion of additional genes, 
such as HIC1, to the three-gene panel 
proposed by Feng et al. might improve 
its sensitivity in detecting high-risk le-
sions that progress. 
 In the context of previously published 
studies and our series, it is premature to 
propose a panel of genes that would be 
the best for screening CIN3/CIS and ICC 
or for identifying high-risk CIN. Before 
such a test based on promoter hyper-
methylation can be proposed for screen-
ing cervical cancer, further studies are 
required on a larger series of specimens 
from different geographical populations, 
and these studies should carefully ad-
dress the issue of false-positive rates. 
 VUNDAVALLI V.  MURTY 
 GOPESHWAR  NARAYAN 
 REFERENCES 
 (1)  Feng Q, Balasubramanian A, Hawes SE, Toure P, 
Sow PS, Dem A, Dembele B, Critchlow CW, 
Xi L, Lu H, McIntosh MW, Young AM, Kiviat 
NB. Detection of hypermethylated genes in 
women with and without cervical neoplasia. 
 J Natl Cancer Inst  2005 ; 97 : 273 – 82. 
 (2)  Dong SM, Kim HS, Rha SH, Sidransky D. 
Promoter hypermethylation of multiple genes 
in carcinoma of the uterine cervix.  Clin Cancer 
Res  2001 ; 7 : 1982 – 6. 
 (3)  Narayan G, Arias-Pulido H, Koul S, Vargas H, 
Zhang FF, Villella J, Schneider A, Terry MB, 
Mansukhani M, Murty VV. Frequent promoter 
methylation of CDH1, DAPK, RARB, and 
HIC1 genes in carcinoma of cervix uteri: its 
relationship to clinical outcome.  Mol Cancer 
 2003 ; 2 : 24 . 
 (4)  Virmani AK, Muller C, Rathi A, Zoechbauer-
Mueller S, Mathis M, Gazdar AF. Aberrant 
methylation during cervical carcinogenesis. 
 Clin Cancer Res  2001 ; 7 : 584 – 9. 
 (5)  Esteller M, Sparks A, Toyota M, Sanchez-
 Cespedes M, Capella G, Peinado MA, 
 Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, 
Baylin SB, Herman JG. Analysis of adeno-
matous polyposis coli promoter hypermethyl-
ation in human cancer.  Cancer Res  2000 ; 60 : 
4366 – 71. 
 (6)  Ferguson AT, Evron E, Umbricht CB,  Pandita 
TK, Chan TA, Hermeking H, Marks JR, 
Lambers AR, Futreal PA, Stampfer MR, 
 Sukumar S. High frequency of hypermethyl-
ation at the 14 – 3 – 3 sigma locus leads to gene 
silencing in breast cancer.  Proc Natl Acad Sci 
U S A  2000 ; 97 : 6049 – 54. 
 (7)  Umbricht CB, Evron E, Gabrielson E, 
Ferguson A, Marks J, Sukumar S. Hypermethy-
lation of 14 – 3 – 3 sigma (stratifi n) is an early event 
in breast cancer.  Oncogene  2001 ; 20 : 3348 – 53. 
 NOTES 
 Affi liation of authors: Department of Pathol-
ogy, Columbia University Medical Center, 
New York, NY. 
 Correspondence to: Vundavalli V. Murty, PhD, 
Department of Pathology, College of Physicians 
& Surgeons of Columbia University, 630 West 
168th St., New York, NY 10032 (e-mail:  vvm2@
columbia.edu ). 
 DOI: 10.1093/jnci/dji317 
 © The Author 2005. Published by Oxford  University 
Press. All rights reserved. For Permissions, please 
e-mail: journals.permissions@oxfordjournals.org. 
 CORRESPONDENCE CO RRESPONDENCE 
 RESPONSE 
 We agree with Murty and Narayan’s 
comment that it is premature to conclude 
that the specifi c panel of genes that we 
reported to be associated with increasing 
severity of cervical cancer among Sen-
egalese women to be generalizable to 
other populations. Studies in lung, liver, 
and gallbladder cancer from different 
geographic sites suggest that the meth-
ylation profi le seen in cancers may vary 
by population and environmental expo-
sures  ( 1 – 3 ) . Clearly, the sensitivity and 
specifi city of our panel of genes need to 
be assessed in cancer and normal tissues 
from various populations. 
 Although Murty and Narayan suggest 
that the high frequency of methylation of 
HIC1, APC, and SFN we observed in 
normal cervical samples is unusual and 
may have obscured an association with 
cervical cancer, others have also reported 
observing methylation of these genes in 
other benign tissues. For example, HIC1 
was methylated in 30% of benign breast 
tissues  ( 5 ) . APC methylation was also 
observed in 30% of normal liver tissues 
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 ( 6 ) , although the level of methylation was 
lower than what was seen in liver cancer 
tissues. Moreover, SFN is known to be 
methylated in normal lymphoid cells  ( 4 ) . 
Because many of our normal samples 
contained infl ammatory infi ltrates as well 
as blood, the high  frequency of promoter 
methylation observed in this gene may be 
attributable to these noncervical cells. 
 Another explanation for the differ-
ence in our respective results may be due 
to the different methods used to detect 
methylation in the two studies. Because 
the methylation-specifi c polymerase chain 
reaction assay we used is not a quan-
titative assay, there may have been a dif-
ference in methylation levels of APC 
and HIC methylation between normal 
and cancer tissues that could not be 
 distinguished. However, unmethylated 
(U)-DNA (human sperm DNA) and 
methylated (M)-DNA (in vitro methyl-
ated human sperm DNA) were included 
as positive and negative controls in all 
experiments. Furthermore, methylation 
of a specifi c gene was considered to be 
present only if both the specimen and the 
M-DNA but not the U-DNA were ampli-
fi ed by methylation-specifi c primers 
 after sodium bisulfate modifi cation. By 
taking such measures, which have not 
been incorporated in many other studies, 
we are confi dent of the specifi city of 
our fi ndings. Finally, the differences ob-
served between our study and that of 
 Narayan et al.  ( 7 ) may be related to the 
use of different primers detecting differ-
ent CpGs within the same CpG island. 
 QINGHUA  FENG 
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